| OR a, b | 95% CI a, c | p-value |
---|---|---|---|
Age at death | 0.985 | 0.98–0.989 | < 0.0001 |
Sex | |||
 Male vs female | 0.95 | 0.87–1.04 | 0.2533 |
Survival in months | 1.01 | 1.006–1.02 | < 0.0001 |
Living in a nursing home | 0.25 | 0.21–0.30 | < 0.0001 |
Care level (reference = no care level) | |||
 1 | 0.47 | 0.42–0.53 | < 0.0001 |
 2 | 0.26 | 0.24–0.29 | < 0.0001 |
 3 | 0.16 | 0.14–0.19 | < 0.0001 |
Healthcare utilisation | |||
 Number of hospital days d | 1.04 | 1.036–1.05 | < 0.0001 |
Palliative Care | |||
 Inpatient palliative care | 1.85 | 1.66–2.08 | < 0.0001 |
 Outpatient palliative care | 0.25 | 0.20–0.32 | < 0.0001 |
Chemotherapy in last 30 days of life | 1.61 | 1.46–1.77 | < 0.0001 |
Charlson Comorbidities Groups | |||
 Congestive Heart Failure | 1.21 | 1.11–1.33 | < 0.0001 |
 Renal Disease | 1.19 | 1.08–1.32 | 0.0006 |
Body regions with Metastases | |||
 Cerebral metastases | 0.86 | 0.77–0.96 | 0.0050 |